Back to search results

Study of ONO-4685 for Relapsed or Refractory T Cell Lymphoma

This study is testing a drug called ONO-4685 for people with T cell lymphoma that has come back (relapsed) or hasn't responded to other treatments (refractory). The main goals are to understand the safety of ONO-4685, how well your body handles it, and if it shows any early signs of helping to treat the cancer. You would receive ONO-4685 through an IV until your disease gets worse or if side effects become too much. The study is looking to enroll about 217 participants aged 18 or older.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 217 participants.
What's involved
You would receive ONO-4685 by IV infusion, continuing until your disease progresses or you experience unacceptable side effects.
Compensation
Not stated in the trial record.
Follow-up
The study will track side effects through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05079282

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
Ono Pharmaceutical Co., Ltd.
~217 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:ONO-4685

At a glance

Recruiting sites
19 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence, nature, and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs).
Measured over Through study completion, an average of 1 year
+1 more outcome measured

Conditions

Relapsed or Refractory T Cell Lymphoma

Explore related trials

Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeFollicular Helper T-Cell Lymphoma, Follicular-TypeMycosis FungoidesNodal PTCL with TFHPTCL-NOSSezary SyndromeT-Cell Non-Hodgkin Lymphoma

NCT05079282

Where you'd take part

This study runs at 20 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope

    Duarte, Californiano site contact published

    Recruiting

  • Cleveland Clinic

    Cleveland, Ohiono site contact published

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusettsno site contact published

    Recruiting

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jerseyno site contact published

    Recruiting

  • Karmanos Cancer Institute

    Detroit, Michiganno site contact published

    Recruiting

  • MD Anderson

    Houston, Texasno site contact published

    Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New Yorkno site contact published

    Recruiting

  • New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC)

    New York, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Project Leader · STUDY_DIRECTOR · Ono Pharmaceutical Co., Ltd.

Who to contact

North America Clinical Trial Support Desk
[email protected]
+18665877745(Toll-Free)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence, nature, and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs).Through study completion, an average of 1 year

    Adverse events with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 used as a guide for the grading of severity.

  • Estimate of Maximum Tolerate Dose (MTD)Up to 3 weeks

    MTD will be estimated based on Dose limiting toxicity (DLT) observed during the first 3 weeks of treatment